Artificial Intelligence is rapidly integrating across pharmaceutical development, manufacturing, and post-market safety systems. While AI offers significant efficiency gains, its use within regulated environments demands robust governance, validation, and oversight.
In this episode of The GMP Insider, we examine the opportunities, risks, and responsibilities associated with AI implementation in pharma quality systems.
Discussion topics include:
• AI applications across drug discovery, clinical data, PV, and manufacturing
• GxP compliance expectations for AI-enabled systems
• Data integrity and audit trail visibility
• Model validation and intended use considerations
• Change control, accountability, and oversight frameworks
• Preventing “black box” risk in regulated environments
AI does not eliminate responsibility — it redistributes it. Quality professionals must ensure that AI tools operate within controlled, transparent, and validated systems.
The future of pharma innovation depends not only on AI capability, but on strong governance structures that protect patient safety and regulatory integrity.